HuM291(nuvion), a humanized Fc receptor-nonbinding antibody against CD3, anergizes peripheral blood T cells as partial agonist of the T cell receptor

Transplantation

Volumn 71, Issue 7, 2001, Pages 941-950

  Chau, Luan A ^c   Tso, J Yun ^a   Melrose, Jennifer ^a   Madrenas, Joaquín ^b  

^a PROTEIN DESIGN LABS INC   (United States)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD69 ANTIGEN; FC RECEPTOR; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HUM291; PROTEIN ERK1; PROTEIN ERK2; PROTEIN TYROSINE KINASE; RAS PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VISILIZUMAB;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; CORRELATION FUNCTION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; IMMUNOMODULATION; NORMAL HUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 0035870674     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200104150-00020     Document Type: Article

References (84)

1. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants
2. Overview of the development of Orthoclone OKT3: Monoclonal antibody for therapeutic use in transplantation
3. Immunologic monitoring during OKT3 therapy
4. Mechanisms of action and overview of OKT3
5. Immunologic monitoring of Orthoclone OKT3-treated patients: The problem of antimonoclonal immune response
6. Humoral immune response against OKT3
7. Antibody response to OKT3 and methods for monitoring
8. In vivo cell activation following OKT3 administration: Systemic cytokine release and modulation by corticosteroids
9. OKT3-induced cytokine-release syndrome: Renal effects (cytokine nephropathy)
10. Cytokine-release syndrome: General risk-factor modification: Preparation of high-risk patients for use of OKT3
11. Phase I evaluation of humanized OKT3: Toxicity and immunomodulatory effects of hOKT3 gamma4
12. A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees
13. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro
14. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection
15. Nonmitogenic anti-CD3F(ab′)2 fragments inhibit lethal murine graft- versus-host disease induced across the major histocompatibility barrier
16. Anti-CD3 F(ab′)2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb
17. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab′)2 fragments of anti-CD3 monoclonal antibody. F(ab′)2 fragments induce a selective T helper dysfunction
18. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties
19. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody
20. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo
21. Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells
22. Formation of a bispecific antibody by the use of leucine zippers
23. Humanized OKT3 antibodies: Successful transfer of immune modulating properties and idiotype expression
24. T cell inactivation and cytokine deviation promoted by anti-CD3 mAbs
25. Induction of apoptosis by anti-CD3 epsilon F(ab′)2 in antigen receptor transgenic murine T cells activated by specific peptide
26. Enhancement of susceptibility to Fas-mediated apoptosis of TH1 cells by nonmitogenic anti-CD3epsilon F(ab′)2
27. Induction of T helper cell hyporesponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody
28. Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets
29. The efficiency of CD4 recruitment to ligand-engaged TCR controls the agonist/partial agonist properties of peptide-MHC molecule ligands
30. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy
31. Differential signaling by variant ligands of the T cell receptor and the kinetic model of T cell activation
32. From TCR engagement to T cell activation: A kinetic view of T cell behavior
33. Ligand-specific oligomerization of T-cell receptor molecules
34. The immunological synapse: A molecular machine controlling T cell activation
35. Costimulation: Building an immunological synapse
36. Altered peptide ligand-induced partial T cell activation: Molecular mechanisms and role in T cell biology
37. Variant TCR ligands: New insights into the molecular basis of antigen- dependent signal transduction and T-cell activation
38. Ligand recognition by alpha beta T cell receptors
39. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells
40. Oncogenes, growth factors, and signal transduction
41. Tyrosyl phosphorylation and activation of MAP kinases by p56lck
42. Dissociation of intracellular signaling pathways in response to partial agonist ligands of the T-cell receptor
43. Phospho-LAT-independent activation of the ras-mitogen-activated protein kinase pathway: A differential recruitment model of TCR partial agonist signaling
44. Partial T cell signaling: Altered phospho-zeta and lack of zap70 recruitment in APL-induced T cell anergy
45. Zeta phosphorylation without ZAP-70 activation induced by TCR antagonists or partial agonists
46. Integration of T cell receptor-dependent signaling pathways by adapter proteins
47. T cell antigen-receptor signal transduction
48. Activation of ZAP-70 kinase activity by phosphorylation of tyrosine 493 is required for lymphocyte antigen receptor function
49. Activating and inhibitory mutations in adjacent tyrosines in the kinase domain of ZAP-70
50. ZAP-70: A 70 kd protein-tyrosine kinase that associates with the TCR zeta chain
51. Tandem SH2 domains of ZAP-70 bind to T cell antigen receptor zeta and CD3 epsilon from activated Jurkat T cells
52. Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling
53. Involvement of p21ras activation in T cell CD69 expression
54. Interleukin 2 production, not the pattern of early T-cell antigen receptor-dependent tyrosine phosphorylation, controls anergy induction by both agonists and partial agonists
55. Interleukin-2 programs mouse alpha beta T lymphocytes for apoptosis
56. Duration of TCR stimulation determines costimulatory requirement of T cells
57. Comparison of in vivo efficacy and mechanism of action of antimutine monoclonal antibodies directed against TCR alpha beta (H57-597) and CD3 (145-2C11)
58. An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity
59. Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): Initial clinical experience
60. T-cell-receptor affinity and thymocyte positive selection
61. A TCR binds to antagonist ligands with lower affinities and faster dissociation rates than to agonists
62. Qualitative and quantitative differences in T cell receptor binding of agonist and antagonist ligands
63. Both high and low avidity antibodies to the T cell receptor can have agonist or antagonist activity
64. Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody
65. Modulation induction of the T3 antigen by OKT3 antibody is monocyte dependent
66. Requirements for T cell activation by OKT3 monoclonal antibody: Role of modulation of T3 molecules and interleukin 1
67. Lymphocyte function in patients treated with monoclonal anti-T3 antibody for acute cadaveric renal allograft rejection
68. Induction of specific nonresponsiveness in unprimed human T cells by anti-CD3 antibody and alloantigen
69. Immunosuppression by OKT3: Induction of programmed cell death (apoptosis) as a possible mechanism of action
70. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells
71. The induction of human T cell unresponsiveness by soluble anti-CD3 mAb requires T cell activation
72. Downregulation of antigen-presenting cell functions after administration of mitogenic anti-CD3 monoclonal antibodies in mice
73. T10B9 (MEDI-500) mediated immunosuppression: Studies on the mechanism of action
74. Differential TCR signaling regulates apoptosis and immunopathology during antigen responses in vivo
75. Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo
76. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis
77. Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ T cells
78. Induction of Th1 and Th2 CD4+ T cell responses: The alternative approaches
79. Distinct biochemical signals characterize agonist- and altered peptide ligand-induced differentiation of naive CD4+ T cells into Th1 and Th2 subsets
80. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice
81. Mature mainstream TCR alpha beta+CD4+ thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse
82. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes
83. Initiation of signal transduction through the T cell receptor requires the multivalent engagement of peptide/MHC ligands
84. The duration of antigenic stimulation determines the fate of naive and effector T cells